ALTIMMUNE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ALTIMMUNE, INC. (ALT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-06
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2018-03-31 was 2.51%.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 0.00% change from fiscal 2024.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 5.26% increase from fiscal 2023.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.80%, a 58.33% increase from fiscal 2022.
- ALTIMMUNE, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.40%, a 200.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | 4.00% 10-K · filed 2026-03-06 | ||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-06 | ||
| 2023-12-31 | 3.80% 10-K · filed 2025-02-27 | ||
| 2022-12-31 | 2.40% 10-K · filed 2024-03-27 | ||
| 2021-12-31 | 0.80% 10-K · filed 2023-02-28 | ||
| 2020-12-31 | 1.20% 10-K · filed 2022-03-15 | 1.24% 10-K · filed 2021-02-25 | |
| 2019-12-31 | 2.17% 10-K · filed 2021-02-25 | ||
| 2018-12-31 | 2.86% 10-K · filed 2020-03-27 | ||
| 2018-03-31 | 2.51% 10-Q · filed 2018-05-15 | ||
| 2017-12-31 | 1.95% 10-K · filed 2019-04-01 | ||
| 2016-12-31 | 2.18% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |